Skip to main content

bgb-b2033

bgb-b2033: 2 clinical trials tracked.

bgb-b2033 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bgb-b2033, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Randomized, Open-Label, Phase 3 Study to Investigate the Efficacy and Safety of BGB-B2033 Compared With Investigator Choice of Sorafenib or Lenvatinib in Patients With Hepatocellular Carcinoma That Progressed Upon Prior Systemic Treatment

NCT07836530Registry updated 2026-09-23·Phase 3·ONC
Not yet recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen492 targetStarted 2026-10Completion 2030-06BeOne Medicines

A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06427941Registry updated 2026-09-16·Phase 1/Phase 2·ONC
Recruiting

Primary endpoint: Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen630 targetStarted 2024-07Completion 2028-1050 sites · Brazil, China, France, Italy…BeOne Medicines